On March 8, 2022 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported the publication of two abstracts for its upcoming poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Cogent Biosciences, MAR 8, 2022, View Source [SID1234609676]). The meeting will be hosted April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first poster presentation will highlight new nonclinical data on the unique properties of bezuclastinib that differentiate it from other KIT inhibitors. Bezuclastinib is currently under clinical investigation in Advanced Systemic Mastocytosis (NCT04996875), Nonadvanced Systemic Mastocytosis (NCT05186753), and imatinib-resistant Gastrointestinal Stromal Tumors (GIST) (NCT05208047). A second poster presentation will reveal in vitro and in vivo characteristics of a novel series of FGFR inhibitors with potency against clinically relevant mutations.

Details for the poster presentations are as follows:

Abstract Number: 147
Title: Bezuclastinib is a differentiated KIT inhibitor that exhibits unique selectivity to KIT A-loop mutations, minimal brain penetration, and favorable pharmacokinetic properties in preclinical models
Session Category: Molecular/Cellular Biology and Genetics
Session Title: Kinases and Phosphatases
Session Date and Time: Sunday, April 10, 2022, 1:30 – 5:00PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 8

Abstract Number: 167
Title: Pre-clinical characterization of a novel series of FGFR2 selective inhibitors with potency against clinically relevant mutations
Session Category: Molecular/Cellular Biology and Genetics
Session Title: Kinases and Phosphatases
Session Date and Time: Sunday, April 10, 2022, 1:30 – 5:00PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 8

On March 8, 2022 Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, reported that it has raised $7 million in Series A financing (Press release, Mytide Therapeutics, MAR 8, 2022, View Source [SID1234609692]). The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon Denominator and the Mytide founding team. As part of the financing, Alloy Therapeutics CEO Errik Anderson will join Mytide’s Board of Directors. This financing will allow Mytide to scale its AI-enabled Gen2 platform to support cost-effective, scalable, and decentralized manufacturing for a wide-variety of peptide and peptide conjugate applications for therapeutic discovery and personal peptide vaccines (PPV).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Together, we are excited to empower developers of peptide and combination therapeutics and enable rapid innovation in this promising modality, for the ultimate benefit of patients."

Mytide’s Gen2 platform produces both natural and non-natural peptides 30-times faster than traditional manufacturing practices by eliminating bottlenecks throughout the entire process of synthesis, analysis, purification, and lyophilization. Through rigorous in-process data collection, Mytide’s continuously learning AI-guided engine enables higher purity, production reliability, and speed, by controlling a proprietary set of chemical processes, analytical tools, and robotics. These tools enable access to a novel peptide space including difficult-to-manufacture non-canonical amino acids, constrained peptides, and short-proteins that are inaccessible or uneconomical to produce and screen using traditional peptide manufacturing processes.

Mytide’s robust data capture and processing techniques represents one of the largest and fastest growing peptide manufacturing data repositories in the world. Through unparalleled manufacturing speed and precision, Mytide’s technology has addressed the high-throughput screening and library generation needs of computational biology modeling to support in vivo and in vitro studies, as well as clinical trial studies.

"At Mytide, we aim to overcome the time-consuming and labor-intensive organic chemistry processes limiting peptide and other biopolymer production. Our goal is to speed drug developers’ ability to translate therapeutic innovations into clinical impact," said Mytide co-founder Dale Thomas. "Our platform takes a holistic view of the entire manufacturing process and couples it with a fully closed-loop computational biology platform, unlocking therapeutic development at unprecedented speeds and precision. The investment from Alloy Therapeutics brings our quick-turn manufacturing technology into a broad drug discovery ecosystem to further accelerate the development of new peptide therapeutics."

Peptides are a high growth drug discovery modality of interest within the pharma industry, with multiple PPVs in Phase III clinical trials. To validate its technology, Mytide has actively partnered its continuous manufacturing platform with pharmaceutical companies requiring scalable and time-sensitive manufacturing for both research and clinical programs. Mytide’s Gen2 platform is designed to easily be integrated into cGMP manufacturing environments to allow for scalable and decentralized clinical trial manufacturing of a partner’s lead peptide-based therapeutic candidates. Mytide continues to advance upon the progress in molecular access and analysis being made by the likes of Integrated DNA Technologies (IDT), Illumina, and Thermo Fisher Scientific.

"Mytide represents an exciting opportunity to bring down barriers in drug development further, by providing Alloy’s ecosystem of industry partners with access to high-quality, AI-enabled peptide manufacturing," said Errik Anderson, Alloy Therapeutics CEO and founder. "Together, we are excited to empower developers of peptide and combination therapeutics and enable rapid innovation in this promising modality, for the ultimate benefit of patients."

On March 8, 2022 Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, reported plans to present new data for multiple research programs across its portfolio of cis-targeted immunotherapies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held in New Orleans, Louisiana, April 8-13, 2022 (Press release, Asher Biotherapeutics, MAR 8, 2022, View Source [SID1234609709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations provide additional data supporting the best-in-class potential of AB248, Asher Bio’s CD8-targeted IL-2 immunotherapy, and further validate the company’s cis-targeting platform, demonstrating its ability to rapidly generate highly selective molecules that target multiple immunomodulators to a diverse set of immune cell types. Asher Bio expects to file an investigational new drug application for AB248, its CD8-targeted IL-2 immunotherapy, in the third quarter of 2022 and for AB821, its CD8-targeted IL-21 immunotherapy, in the second half of 2023.

Details of the poster presentations are as follows:

Presentation Title: AB248 is a CD8+ T cell selective IL-2 designed for superior safety and anti-tumor efficacy
Session Title: Immunomodulatory Agents and Interventions 2
Session Date & Time: Tuesday, April 12, 2022 from 1:30 p.m. – 5:00 p.m. CT (11:30 a.m. – 3:00 p.m. PT)
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 3518

Title: Selective activation of CD8+ T cells by a CD8-targeted IL-21 results in enhanced anti-tumor efficacy and safety
Session Title: Therapeutic Antibodies 1
Session Date & Time: Tuesday, April 12, 2022 from 9:00 a.m. – 12:30 p.m. CT (7:00 a.m. – 10:30 a.m. PT)
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 2882

Title: CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy
Session Title: Adoptive Cell Therapy 1
Session Date & Time: Sunday, April 10, 2022 from 1:30 p.m. – 5:00 p.m. CT (11:30 a.m. – 3:00 p.m. PT)
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36
Abstract Number: 561

The abstracts are now available on the AACR (Free AACR Whitepaper) conference website.

On March 8, 2022 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that pre-clinical data on JZP815, an investigational, next-generation pan-RAF kinase inhibitor, will be presented as a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting from April 8-13, 2022 (Press release, Jazz Pharmaceuticals, MAR 8, 2022, View Source [SID1234609726]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Together with our pre-clinical collaboration partner, Redx Pharma, we look forward to presenting at AACR (Free AACR Whitepaper) our first pre-clinical data on JZP815, which demonstrated that it selectively and potently inhibits mutant A, B and CRAF kinases, and demonstrated anti-tumor activity in RAS- and RAF-mutant xenograft models," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "The pan-RAF inhibitor program is part of a novel class of next generation precision oncology therapies that has the potential to benefit cancer patients with high unmet needs in multiple different solid tumors. We look forward to progressing JZP815 to the clinic to further evaluate the benefit it may have for appropriate patients."

The Jazz presentation abstract – titled, "JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models" – and the AACR (Free AACR Whitepaper) 2022 Annual Meeting details are available here.

Activation of the mitogen-activated protein kinase (MAPK) pathway by oncogenic mutations in RAS and RAF is a frequent driver of cancer. Targeting specific components of the pathway can be a precise and rational route to deliver benefits to cancer patients with high unmet needs. The RAF kinase proteins (ARAF, BRAF, CRAF) are core pathway components that mediate MAPK signaling. Mutations in these critical signaling proteins leads to constitutive activation of the MAPK pathway and tumor growth.

JZP815 is an investigational, pre-clinical stage, next-generation pan-RAF kinase inhibitor that was discovered and developed using state-of-the-art screening methodologies and medicinal chemistry. JZP815 is not currently approved for use anywhere in the world.

Jazz acquired JZP815 from Redx Pharma, and the two companies are collaborating on this pre-clinical research. Jazz plans to submit an IND for JZP815 this year. JZP815 is part of Jazz’s growing early-stage R&D pipeline focused on precision oncology in solid tumors.

On March 8, 2022 Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinicalstage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported that preclinical data from its VaccibodyTM vaccine platform technology will be presented at the upcoming 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana (Press release, Nykode Therapeutics, MAR 8, 2022, View Source [SID1234609768]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:
Abstract #: 3558
Title: A novel and versatile cytokine empowered DNA vaccine platform with superior immune activating potential Authors: Beraas, et al.
Session Title: Vaccines: Oncolytic and Prophylactic
Session Date and Time: Tuesday, April 12, 2022 | 1:30 p.m. – 5:00 p.m. ET

The abstract is available in the Scientific Papers and Presentations section of the Company’s website. The e-poster will be available on the Company’s website on Friday, April 8, 2022.